The HemOnc Pulse

Rahul Banerjee, MD
  • 0,0 (0)
  • Vetenskap
  • Varje månad

Blood Cancers Today and the Society of Hematologic Oncology bring you The HemOnc Pulse, a podcast hosted by Rahul Banerjee, MD, covering all topics in the world of hematologic oncology.

  1. 8 juni

    Community-Based CAR-T Therapy: Expanding Access, Navigating Challenges

    In this episode of HemOnc Pulse, host Dr. Rahul Banerjee of Fred Hutchinson Cancer Center sits down with Dr. Gary Simmons, a hematologist-oncologist at Virginia Oncology Associates, to explore the evolving role of community-based cellular therapy programs and the future of patient access to innovative treatments.

  2. 30 mars

    Cutting GVHD Risk: What’s Changing in Allogeneic Transplants?

    Learn how new approaches in allogeneic transplants, from PTCy to innovative regimens, are helping reduce GVHD and improve patient outcomes with special guest Sagar S. Patel, MD of University of Utah Health.

  3. 7 feb.

    MRD at the Regulatory Crossroads in Multiple Myeloma

    In this Editor’s Special Episode of The HemOncPulse, a conversation with Nicholas Richardson, DO, MPH, vice president of clinical development at Precision for Medicine, focuses on the evolving regulatory role of measurable residual disease in multiple myeloma clinical trials. The discussion is designed to contextualize recent FDA draft guidance for a broad clinical and research audience.

  4. 27 jan.

    The Data Problem in T-Cell Lymphoma Care

    In this episode of TheHemOnc Pulse, Rahul Banerjee, MD, speaks with Francine Foss, MD, professor of medicine and dermatology at Yale School of Medicine, about the evolving landscape of T-cell lymphomas. Dr Foss discusses the unique challenges of studying and treating rare diseases such as cutaneous T-cell lymphoma and explains why real-world data are essential to closing evidence gaps. The conversation highlights the role of collaborative registries in tracking treatment patterns, outcomes, and access to care across community and academic settings. Dr Foss also shares how both clinicians and patients can participate in these efforts to strengthen research, inform future clinical trials, and improve outcomes for patients with T-cell lymphomas.

  5. 2025-12-26

    XPO1 Inhibition Across the Myeloma Journey

    This Editor’s Special Episode of The HemOnc Pulse features Paul G. Richardson, MD, of Dana-Farber Cancer Institute, discussing treatment strategies for relapsed/refractory multiple myeloma and where selinexor-based regimens fit in today’s evolving landscape. Drawing from real-world cases, Dr. Richardson explores care for patients before CAR T, after CAR T relapse, and in between—highlighting how selinexor can be used flexibly across multiple lines, including as a bridge to future immunotherapies. The conversation emphasizes individualized, dynamic treatment planning to balance disease control, tolerability, and long-term goals in an increasingly complex era of myeloma care.

  6. 2025-12-20

    Holding the Line in AML: Real-World Care Meets Breakthrough Trials

    Dr. Eunice Wang joins host Rahul Banerjee, MD, for a clinician-focused discussion on AML, treatment complexity, and real-world leukemia management in today’s evolving therapeutic landscape.

  7. 2025-10-17

    Under the Hood: Exploring the Genomic Engines of Smoldering Myeloma

    In this episode of The HemOnc Pulse, host Melissa speaks with Omar Nadeem, MD, Senior Physician at Dana-Farber Cancer Institute and Assistant Professor of Medicine at Harvard Medical School, about emerging genomic insights in smoldering multiple myeloma. The discussion focuses on recent research showing how molecular profiling can improve understanding of disease progression and refine risk stratification beyond traditional clinical models. Dr. Nadeem highlights how genomic data may help distinguish patients with smoldering myeloma who are at higher risk of progression from those likely to remain stable, offering the potential to guide more personalized treatment decisions. The conversation also explores the evolving landscape of precursor plasma cell disorders and the role of immunotherapy, including CAR T-cell therapy, in clinical management.

  8. 2025-10-03

    Toxicity, Time, and the Patient Experience in Blood Cancers

    Dr. Rahul Banerjee interviews Dr. Ajay Major on patient-reported outcomes, toxicity reporting, and patient engagement in blood cancer clinical trials.

Visa alla (85)

Om

Blood Cancers Today and the Society of Hematologic Oncology bring you The HemOnc Pulse, a podcast hosted by Rahul Banerjee, MD, covering all topics in the world of hematologic oncology.

Information

  • Skapad av
    Rahul Banerjee, MD
  • Aktiva år
    2022 - 2026
  • Avsnitt
    85
  • Åldersgräns
    Barnvänligt
  • Copyright
    © Copyright 2025 All rights reserved.
  • Programmets webbplats
    The HemOnc Pulse